Esperion Therapeutics (ESPR)

P/S ratio as of November 2024 (TTM): 1.75

According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.41. At the end of 2024 the company had a P/S ratio of 1.51.

P/S ratio history for Esperion Therapeutics from 2013 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	1.51	-48.2%
2023	2.92	-51.95%
2022	6.08	56.69%
2021	3.88	31.08%
2020	2.96	-73.21%
2019	11.1
2018	N/A
2017	N/A
2016	N/A
2015	N/A
2014	N/A
2013	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Ultragenyx RARE	8.83	403.98%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	4.39	150.73%	🇺🇸 USA
Pfizer PFE	2.56	46.09%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	5.91	237.24%	🇺🇸 USA
Amicus Therapeutics FOLD	6.23	255.59%	🇺🇸 USA
Lexicon Pharmaceuticals LXRX	76.6	4,273.20%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Esperion Therapeutics (ESPR)

P/S ratio as of November 2024 (TTM): 1.75